About voyager therapeutics inc - VYGR
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.
VYGR At a Glance
Voyager Therapeutics, Inc.
75 Hayden Avenue
Lexington, Massachusetts 02421
| Phone | 1-857-259-5340 | Revenue | 40.37M | |
| Industry | Biotechnology | Net Income | -119,721,000.00 | |
| Sector | Health Technology | Employees | 141 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
VYGR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.713 |
| Price to Book Ratio | 1.183 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.553 |
| Enterprise Value to Sales | 1.751 |
| Total Debt to Enterprise Value | 0.516 |
VYGR Efficiency
| Revenue/Employee | 286,340.426 |
| Income Per Employee | -849,085.106 |
| Receivables Turnover | 13.85 |
| Total Asset Turnover | 0.125 |
VYGR Liquidity
| Current Ratio | 7.637 |
| Quick Ratio | 7.637 |
| Cash Ratio | 7.402 |
VYGR Profitability
| Gross Margin | 89.944 |
| Operating Margin | -326.557 |
| Pretax Margin | -296.173 |
| Net Margin | -296.53 |
| Return on Assets | -37.104 |
| Return on Equity | -48.29 |
| Return on Total Capital | -51.475 |
| Return on Invested Capital | -42.681 |
VYGR Capital Structure
| Total Debt to Total Equity | 18.614 |
| Total Debt to Total Capital | 15.693 |
| Total Debt to Total Assets | 14.468 |
| Long-Term Debt to Equity | 14.616 |
| Long-Term Debt to Total Capital | 12.322 |